Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.

Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma. - Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010000

Enrollment

150

Registered

2013-02-08

Start date

2012-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced hepatocellular carcinoma who are to be treated with sorafenib and from whom written informed consent was obtained.

Exclusion criteria

Exclusion criteria: Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 and pretreatment Child-Pugh score of 8 or more.

Design outcomes

Primary

Measure	Time frame
The clinicopathological factors related to time to progression of unresectable advanced hepatocellular carcinoma.patients treated with sorafenib.	—

Secondary

Measure	Time frame
The clinicopathological factors related to overall survival of unresectable advanced hepatocellular carcinoma patients treated with sorafenib. The clinicopathological factors to predict serious adverse effects caused by sorafenib.	—

Countries

Japan

Contacts

Public ContactYukio Osaki

Osaka Red Cross Hospital department of Gatroenterology and Hepatology

06-6774-5111

Outcome results